Citius Pharmaceuticals (CTXR) Receives a Buy from Dawson James

In a report issued on December 6, Jason Kolbert from Dawson James maintained a Buy rating on Citius Pharmaceuticals (CTXRResearch Report), with a price target of $10.00. The company’s shares closed last Tuesday at $1.69.

According to TipRanks.com, Kolbert is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Sorrento Therapeutics, and Anavex Life Sciences.

Citius Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.00, representing a 311.8% upside. In a report issued on November 30, Maxim Group also initiated coverage with a Buy rating on the stock with a $4.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $4.56 and a one-year low of $0.97. Currently, Citius Pharmaceuticals has an average volume of 2.07M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Read More on CTXR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed